Business

October 22nd 2026

Panelists at an IGBA Global Biosimilars Week webinar detailed worldwide access gains and adoption barriers.

September 24th 2026

The Association for Accessible Medicines report, prepared with the IQVIA Institute, also reports $25.4 billion in biosimilar savings for the year.

August 28th 2026

A study found no direct trial evidence for natalizumab or its biosimilar in MS and found limited cost-effectiveness vs most alternatives.

August 4th 2026

Biosimilar denosumab cleared a $150,000 per QALY cost-effectiveness threshold against bisphosphonates for high-risk PMO, but not always at $100,000.